TLX 0.91% $16.61 telix pharmaceuticals limited

This from Bell Potter: “The short-term outlook for revenue...

  1. 64 Posts.
    lightbulb Created with Sketch. 11
    This from Bell Potter: “The short-term outlook for revenue growth from the diagnostic assets remains attractive, nevertheless the major inflection points for TLX591 in the treatment of prostate cancer are close and carry significant clinical risk. We expect a readout on the important efficacy measure of progression free survival within the next 2 to 3 months. A poor clinical readout has the potential to materially impact the share price and accordingly we downgrade from Buy to Hold on the basis of valuation, noting this is the first recommendation downgrade since our initiation coverage in 2021.”
 
watchlist Created with Sketch. Add TLX (ASX) to my watchlist
(20min delay)
Last
$16.61
Change
0.150(0.91%)
Mkt cap ! $5.549B
Open High Low Value Volume
$16.50 $16.86 $16.02 $30.84M 1.870M

Buyers (Bids)

No. Vol. Price($)
2 3364 $16.61
 

Sellers (Offers)

Price($) Vol. No.
$16.63 2703 2
View Market Depth
Last trade - 16.10pm 14/06/2024 (20 minute delay) ?
Last
$16.64
  Change
0.150 ( 0.47 %)
Open High Low Volume
$16.49 $16.86 $16.02 314899
Last updated 15.59pm 14/06/2024 ?
TLX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.